blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4103725

EP4103725 - METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  18.11.2022
Database last updated on 10.07.2024
FormerThe international publication has been made
Status updated on  20.08.2021
Most recent event   Tooltip28.02.2024Supplementary search reportpublished on 27.03.2024  [2024/13]
Applicant(s)For all designated states
Asklepios Biopharmaceutical, Inc.
20 T.W. Alexander Drive, Suite 110
Research Triangle Park, NC 27709 / US
[2022/51]
Inventor(s)01 / HOPKINS, Sam
Research Triangle Park, North Carolina 27709 / US
02 / ERVIN, Leigh
Research Triangle Park, North Carolina 27709 / US
 [2022/51]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2022/51]
Application number, filing date21753409.812.02.2021
[2022/51]
WO2021US17818
Priority number, dateUS202062976755P14.02.2020         Original published format: US 202062976755 P
[2022/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021163451
Date:19.08.2021
Language:EN
[2021/33]
Type: A1 Application with search report 
No.:EP4103725
Date:21.12.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 19.08.2021 takes the place of the publication of the European patent application.
[2022/51]
Search report(s)International search report - published on:US19.08.2021
(Supplementary) European search report - dispatched on:EP27.02.2024
ClassificationIPC:C12N15/86, C12N15/867, C12N15/869
[2022/51]
CPC:
A61K48/005 (EP); A61K31/65 (EP,US); A61K31/573 (EP,US);
A61K38/47 (US); A61K45/06 (EP); A61P39/00 (US);
C12N15/86 (EP,US); C12N9/2402 (US); C12Y302/0102 (EP,US);
C12N2750/14143 (EP,US); C12N2750/14171 (US) (-)
C-Set:
A61K31/573, A61K2300/00 (EP);
A61K31/65, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/51]
TitleGerman:VERFAHREN ZUR BEHANDLUNG EINER GENTHERAPIEASSOZIIERTEN TOXIZITÄT MIT ANTIBIOTIKA[2022/51]
English:METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS[2022/51]
French:PROCÉDÉ DE TRAITEMENT D'UNE TOXICITÉ ASSOCIÉE À UNE THÉRAPIE GÉNIQUE AVEC DES ANTIBIOTIQUES[2022/51]
Entry into regional phase01.09.2022National basic fee paid 
01.09.2022Search fee paid 
01.09.2022Designation fee(s) paid 
01.09.2022Examination fee paid 
Examination procedure01.09.2022Examination requested  [2022/51]
06.03.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
01.09.2022Renewal fee patent year 03
12.01.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US2014271549  (SZALAY ALADAR A [US]) [X] 1-15 * paragraph [0003] - paragraph [0008] * * paragraph [0202] - paragraph [0223] * * paragraph [0225] - paragraph [0229] *;
 [A]WO2018227286  (SINAI HEALTH SYS [CA]) [A] 1-15* page 87, line 16 - page 88, line 17 *
International search[Y]US6346415  (FELDHAUS ANDREW L [US]) [Y] 12 * ; col 6, In 63-col 7, In 3; claim 25 *;
 [Y]US6987093  (DUNNE MICHAEL WILLIAM [US]) [Y] 5-7, 19, 20-22 * ; col 1, In 11-12; col 1, In 16-18 *;
 [Y]WO2016025010  (UGWU MARTIN [US]) [Y] 6, 20, 22* ; Abstract *;
 [XY]WO2017218981  (ADVERUM BIOTECHNOLOGIES INC [US]) [X] 1-4, 8-10, 13-14, 16-18, 23-25 * Abstract; para [0003], [0006], [0007], [0043], [0071], [0074], [0139], [0178], claim 2, 24 * [Y] 5-7, 12, 19-22
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.